Linagliptin

Inoa Kimia:

8-[(3R)-3-aminopiperidin-1-yl]-7-(akā-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3 ,7-dihydro-1H-purine-2,6-dione

SMILES Code:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O

Code InChi:

InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21 )34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2 ,1-3H3/t17-/m1/s1

Ki InChi:

LTXREWYXXSTFRX-QGZVFWFLSA-N

huaʻōlelo:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Hiki ke hoʻoheheʻe:Hiki ke hoʻoheheʻe ʻia ma DMSO

Waihona:0 - 4°C no ka wā pōkole (nā lā i nā pule), a i ʻole -20°C no ka wā lōʻihi (mau mahina).

wehewehe:

ʻO Linagliptin, ka mea i kapa ʻia ʻo BI-1356, he mea pale DPP-4 i hoʻomohala ʻia e Boehringer Ingelheim no ka mālama ʻana i ka maʻi diabetes type II. Ua ʻae ʻia ʻo Linagliptin (hoʻokahi lā i kēlā me kēia lā) e ka US FDA ma 2 Mei 2011 no ka mālama ʻana i ka maʻi diabetes type II. Ke kūʻai ʻia nei e Boehringer Ingelheim a me Lilly.

Pahuhopu: DPP-4